YIPI, SPPH, WEST, CBIS, IDGC, IMDS, BPAX OTCPicks.com Daily Market Movers Digest Midday Report for Tuesday, June 5th
6/5/2012 12:49:53 PM
Stocks to Watch today include Yippy Inc. (OTCQX: YIPI), Spencer Pharmaceutical
Inc. (OTC: SPPH), Westinghouse Solar Inc. (NASDAQ: WEST), Cannabis Science Inc.
(OTCBB: CBIS), IDGLOBAL Corp. (OTC: IDGC), Imaging Diagnostic Systems Inc.
(OTCBB: IMDS) and BioSante Pharmaceuticals Inc. (OTC: BPAX).
to register for our Daily Market Mover’s Digest Newsletter and Email Stock
INCORPORATED (OTCQX: YIPI)
11.54% in morning trading"
in Fort Myers, Florida, Yippy, Inc. is a new economy technology company that
develops educational and reference search technologies, content aggregation services
and application services environments for both consumer and commercial market
segments. The Company operates several online web properties and educational
reference portals. Yippy, Inc. has been approved to trade on the OTCQX U.S.,
the intelligent marketplace for the best OTC companies with the highest
financial standards and superior information availability. The Company began
operations in 2009.
4 - Yippy, Inc. (YIPI) signs Binding LOI to Acquire Macte Labs, Inc.
Inc. (OTCQX: YIPI) (www.yippy.com) ("Yippy" or the
"Company"), providers of the world's fastest, family-friendly search
engine and web portal reported that the Company has entered into a binding
letter of intent to acquire 100% of Macte Labs. Terms of deal will be released
upon closing on or about 6/30/2012.
Granville, CEO, Yippy, Inc. states, "Macte Labs depth in custom designed
browser extensions was quite apparent when we began talks back in early April
2012. The majority of Consumer, Vertical and Enterprise search functions are
performed through a toolbar or add-on extension. Macte possesses
significant advantages to competitors like Conduit and provides a more stable
and user friendly platform from which to engage consumers. The NeoBar project
is the genesis for a new breed of toolbar extensions and we are only too happy
to own this amazing technology."
Kuzmin, CEO, Macte! Labs, Inc, commented, "The NeoBar platform provides
the most versatile of all current toolbar solutions. Our fully documented toolbar
extensions performs well on all major browsers such as IE, Firefox, Safari,
Opera and Chrome. With unique abilities to apply monetization solutions such as
affiliate commerce, interactive advertising and paid search, the NeoBar may be
the most powerful browser extensions platform in the world."
NeoBar project includes but not limited to the following:
True subscriber-webpage integration providing complete client engagement, with
the ability to offer subscribers enhanced/safe web search capabilities,
vertical search solutions and support for secure on-line commerce.
Interactive real-time communication - the ability for clients to relay
important information to their subscribers when they need it, no matter what
they are doing on the web, such as latest news, stock data and reward points.
Dynamic end user experience for the subscriber - NeoBars can displayed and
formatted in an infinite number of ways based on subscriber's contextual
searches, demographics, geographic and or community preferences.
added, "We are extremely excited at the opportunity to integrate the
NeoBar dynamic, interactive and vertical development platform with the dynamic,
interactive and vertical search capabilities of Yippy. The Synergies between
our two companies are astounding and present a huge market opportunity."
MACTE! LABS, INC.
Labs (www.mactelabs.com) is a leading developer of dynamic toolbars and web
applications that provided clients with enhanced, interactive and visually
appealing vertical search and client communication solutions. Macte Labs has 20
employees in 3 countries and is headquartered in Vancouver BC, Canada. Macte!
Labs was founded in 2008.
PHARMACEUTICAL INCORPORATED (OTC: SPPH)
680.00% in morning trading"
Pharmaceutical Inc. develops drug platform technologies for the treatment of
neurological deceases. The company specializes in the controlled release of
existing therapeutic molecules in the areas of central nervous system, which
include Alzheimer and Parkinson diseases, and brain cancer; and patented slow
release drug delivery technology for the treatment of type-2 diabetes,
arthritis, and other potential applications. It has operations primarily in
North America and Europe. The company was incorporated in 1998 and is based in
recent news for Spencer Pharmaceutical Inc. (OTC: SPPH ).
SOLAR INCORPORATED (NASDAQ: WEST)
22.22% in morning trading"
Solar is a designer and manufacturer of solar power systems. In 2007,
Westinghouse Solar pioneered the concept of integrating the racking, wiring and
grounding directly into the solar panel. This revolutionary solar panel,
originally branded "Andalay", quickly won industry acclaim. In 2009,
the company again broke new ground with the first integrated AC solar panel,
reducing the number of components for a rooftop solar installation by
approximately 80 percent and lowering labor costs by approximately 50 percent.
This first AC panel, which won the 2009 Popular Mechanics Breakthrough Award,
has become the industry's most widely installed AC solar panel. Award-winning
Westinghouse Solar Power Systems provide the best combination of safety,
performance and reliability, while backed by the proven quality of the
5 - Westinghouse Solar and CBD Energy to Distribute Systems in Australia
Solar, Inc. (NASDAQ: WEST), a designer and manufacturer of integrated rooftop
solar power systems, and CBD Energy Ltd. (ASX: CBD), a diversified renewable
energy company, jointly announced plans to begin distributing Westinghouse
Solar Power Systems in Australia. This follows last week's announcement of the
settlement of all disputes between Westinghouse Solar and Zep Solar.
Solar CEO Margaret Randazzo commented, "In parallel with our efforts to
complete our pending merger with CBD, both companies are committed to growing
the business in a collaborative effort. As a first step, CBD, through its solar
subsidiaries, has agreed to market and install our solar power systems in the
Australian and other international markets. The Australian market enjoys a
sound regulatory environment for solar, and provides an opportunity for us to
grow revenue in a non-US market devoid of risk of punitive tariffs".
key reason for pursuing this merger was the strength of the award winning
technology that Westinghouse Solar possesses," said Gerry McGowan,
Managing Director and CEO of CBD. "When coupled with the significant brand
awareness the Westinghouse name provides, one of the first items on our agenda
was to bring these integrated 'plug-and-play' solar power systems, with fewer
parts, superior safety and faster install times to the Australian market. After
demonstrating the technology to our customers, they have shown strong interest
and we are working to make this innovative technology available to them as soon
as possible. Other key features such as the web-based system monitoring and
better energy collection will be important advantages in the Australian market,
which installed in excess of 830 megawatts of solar last year. In short, I
believe the Westinghouse Solar product to be a class leader," Mr. McGowan
Solar plans to begin shipping to CBD in the third quarter of this year. Further,
the companies have been working on future plans to assemble Westinghouse Solar
products in Australia using CBD's newly established solar panel manufacturing
Head of Strategy Carlo Botto said "In the past five years, electricity
prices have risen at four times the rate of inflation in Australia. Recently
released research by an industry association has shown household electricity
charges are already 70% higher than the American average, a figure that is
expected to grow to 160% in two years. These increases include the cost of the
recently legislated carbon tax, which is expected to add an additional 11% to
average power bills, and then increase year-on-year. Roof-top solar generation
will play an increasingly important role in assisting Australia's households
and businesses to mitigate against volatile and ever-increasing energy
SCIENCE INCORPORATED (OTCBB: CBIS)
20.77% in morning trading"
Science Inc. is at the forefront of medical marijuana research and development.
The company works with world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to develop,
produce, and commercialize phytocannabinoid-based pharmaceutical products. It
is dedicated to the creation of cannabis-based medicines, both with and without
psychoactive properties, to treat disease and the symptoms of disease, as well
as for general health maintenance.
5 - Cannabis Science Initiates HIV TAT Anti-Viral Drug Development Program;
CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept
Company will Focus on Pre-Clinical Facilitation of Target Validation Proof of
Concept of TAT Inhibition, Structure Activity Relationships for Compound
Identification Based on Fragment Lead Discovery through Collaborations with
Leading Scientific Institutions
Science (OTCBB: CBIS) announced the initiation of a research program to explore
the commercial development of Phytocannabinoid-based therapeutics for drug
resistant HIV infection. The program will facilitate an antiviral investigation
of Phytocannabinoids inhibition of HIV TAT. Cannabis Science is a publicly
traded, pioneering U.S. Biotech Company developing pharmaceutical products for
global public health challenges.
New scientific data supports Phytocannabinoid inhibition of HIV TAT
An initial discovery program will identify structural and medicinal
biochemistry of CS-TATI-1 inhibition of TAT
Formation of a Scientific Advisory Board (SAB) and Collaborative Research and
Development Agreement (CRADA) to facilitate initial research
Research Provides Clue to New Strategy for Inhibiting HIV Replication
published in March by researchers at the Mount Sinai School of Medicine found
that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2
receptors (CB2). Funding for the Mount Sinai study was provided by a National
Institutes of Health (NIH) Clinical and Translational Science Award Grant.
Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients
infected with drug resistant virus, treatment experienced patients with
drug-resistant HIV strains, and those intolerant of currently available
to market for CS-TATI-1
Science will be pursuing a wide range of NIH based Federal Research Programs
such as RO1’s, PO1’s and SBIRS which exist to support preclinical development
of target validation and proof of concept studies. These studies will be
implemented through collaborations with leading scientific institutions.
Cannabis Science will also be pursuing other clinical research collaborations
including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial
Network (CATN) and the European AIDS Trial Network (EATN).
Melamede, President and CEO of Cannabis Science Inc., states, “Cannabis Science
is dedicated to the development of the first Phytocannabinoid-based treatment
for HIV. Our program is based on the initial identification of antiviral
activity of Phytocannabinoids against TAT activity. Cannabinoids have
demonstrated an inhibitory effect on the progression of HIV expression by
interfering with the critical functions of TAT. The Company will pursue various
Federal research initiatives that will help fund the initial medicinal
chemistry characterization of cannabinoid TAT inhibition.”
Science is currently in the process of forming an eminent Scientific Advisory
Board (SAB) for the CS-TATI-1 program. The SAB will include several leaders in
HIV research and commercial drug development.
THE GLOBAL HIV/AIDS PANDEMIC
ability to mutate and reproduce itself even in the presence of antiretroviral
drugs, has led to a growing rate of drug resistance. Increasing drug resistance
is severely limiting treatment options for HIV patients around the world,
increasing direct and indirect health costs, furthering the spread of drug
resistant strains of HIV and is creating a pressing need to develop new HIV
U.S. government invests billions of dollars a year in HIV/AIDS research,
treatment and care through a variety of programs. The Ryan White CARE Act,
which funds the treatment and care of people living with HIV in the U.S.,
totals $2.3 billion a year. Among its many other contributions to fighting
HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S.
Military HIV Research Program and approximately $1 billion per year to The
Global Fund to Fight AIDS, Tuberculosis and Malaria.
sales to treat HIV equal US $10.6 billion annually. Treatment cost per patient
in the U.S. for HIV antivirals alone is approximately US $15,000 a year.
CORPORATION (OTC: IDGC)
200.00% in morning trading"
provides a range of leading technologies specifically designed to provide
private enterprise and governments 100% solutions to their Counterfeiting and
Loss Prevention / Anti-Theft security programs. IDGLOBAL’s Nano-Molecular
Markers / Tags™ are specifically designed for global anti-counterfeiting
applications and its IDFORENSIX™ products provide Loss Prevention / Anti-Theft
recent news for IDGLOBAL Corp. (OTC: IDGC).
DIAGNOSTIC SYSTEMS (OTCBB: IMDS)
25.00% in morning trading"
Diagnostic Systems, Inc. has developed a revolutionary new imaging device to
aid in the detection and management of breast cancer. The CTLM® system is a
breast imaging system that utilizes patented continuous wave laser technology
and computer algorithms to create 3-D images of the breast. The procedure is
non-invasive, painless, and does not expose the patient to ionizing radiation
or painful breast compression. CT Laser Mammography (CTLM®) is designed to be
used in conjunction with mammography. It reveals information about blood
distribution in the breast and shows the process of angiogenesis, which usually
accompanies tumor growth. CTLM system has received international certifications
and licenses from the European CE mark, CMDCAS Canadian Health screening, China
SFDA, India, UL, and ISO 13485. The Company is seeking FDA approval through the
Premarket approval process.
22 - Imaging Diagnostic's Non-Invasive CTLM® Laser Breast Imaging Device Will
Soon Be Available to Women in Kuwait
Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser breast imaging,
announced that it has signed a distribution agreement with Mareen Group to
market and sell its Computed Tomography Laser Mammography (CTLM®) System in
Group is honored to present the CTLM® to the women of Kuwait. We are eager to
support the imaging needs of patients through this dignified and innovative
laser breast imaging modality," commented Ahmad Abdulrahman, General
Manager of Mareen Group.
Group is a Medical & Pharmaceutical distribution company well established
and based in Kuwait. They have been in operation since 1998, proudly providing
various medical and healthcare institutions within Kuwait and the surrounding
areas with advanced medical equipment and pharmaceuticals from across the
globe. The philosophy of Mareen Group has always been to build close ties with
their customers by supporting their every need with prompt professional service
Diagnostic's CEO, Linda Grable, states, "IDSI is delighted to assign
Mareen Group, a well established medical company in Kuwait, as our new
distributor. The women in Kuwait will hopefully benefit from CTLM®'s unique and
discrete breast imaging process to aid in the diagnosis and management of
breast abnormalities. We are enthusiastic to work with Mareen Group to make the
CTLM®, a non-invasive alternative, accessible to women in Kuwait."
PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX)
20.90% in morning trading"
is a specialty pharmaceutical company focused on developing products for female
sexual health, menopause, contraception and male hypogonadism. BioSante's lead
products include LibiGel® (transdermal testosterone gel) in Phase III clinical
development by BioSante under a U.S. Food and Drug Administration (FDA) SPA
(Special Protocol Assessment) for the treatment of female sexual dysfunction
(FSD), and Elestrin™ (estradiol gel) developed through FDA approval by
BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, currently marketed in the U.S. Also in development
are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral
contraceptive in Phase II clinical development using BioSante patented
technology. The current market in the U.S. for estrogen and testosterone
products is approximately $2.5 billion and for oral contraceptives
approximately $3.0 billion. The company also is developing its calcium
phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic
medicine (BioLook™). Additional information is available online at
4 - BioSante Pharmaceuticals, Inc. to Present at Jefferies Global Healthcare
Pharmaceuticals, Inc. (OTC: BPAX) announced that Stephen M. Simes, BioSante’s
president & CEO will present a corporate update at the Jefferies 2012
Global Healthcare Conference in New York on June 6, 2012 at 11:00 am EDT.
Simes will provide an overview of BioSante, as well as an update on the
LibiGel® (testosterone gel) Phase III clinical development program, and a
review of published results using BioSante’s GVAX Cancer Immunotherapies in
combination with ipilimumab (Ipi; Yervoy; BMS).
OTCPicks.com is located at 3533 Twin Lakes
Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email
NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We
are not registered as a securities broker-dealer or an investment adviser
either with the U.S. Securities and Exchange Commission (the "SEC")
or with any state securities regulatory authority. We are neither licensed nor
qualified to provide investment advice. OTCPicks.com makes no recommendation
that the purchase of securities of companies profiled in this web site is
suitable or advisable for any person or that an investment such securities will
be profitable. In general, given the nature of the companies profiled and the
lack of an active trading market for their securities, investing in such
securities is highly speculative and carries a high degree of risk. You are
receiving this email because you have registered on OTCPicks.com or one of our
information contained in our report should be viewed as commercial
advertisement and is not intended to be investment advice. The report is not
provided to any particular individual with a view toward their individual
circumstances. The information contained in our report is not an offer to buy
or sell securities. We distribute opinions, comments and information free of
charge exclusively to individuals who wish to receive them.
newsletter and website have been prepared for informational purposes only and
are not intended to be used as a complete source of information on any
particular company. An individual should never invest in the securities of any
company profiled based solely on information contained in our reports. Individuals
should assume that all information contained in the report about profiled
companies is not trustworthy unless verified by their own independent research.
individual who chooses to invest in any securities should do so with caution.
Investing in securities is speculative and carries a high degree of risk; you
may lose some or all of the money that is invested. Always research your own
investments and consult with a registered investment advisor or licensed stock
broker before investing.
contained in our report will contain "forward looking statements" as
defined under Section 27A of the Securities Act of 1933 and Section 21B of the
Securities Exchange Act of 1934. Subscribers are cautioned not to place undue
reliance upon these forward-looking statements. These forward looking
statements are subject to a number of known and unknown risks and uncertainties
outside of our control that could cause actual operations or results to differ
materially from those anticipated. Factors that could affect performance
include, but are not limited to, those factors that are discussed in each
profiled company's most recent reports or registration statements filed with
the SEC. You should consider these factors in evaluating the forward looking
statements included in the report and not place undue reliance upon such
statements. We are committed to providing factual information on the companies
that are profiled. However, we do not provide any assurance as to the accuracy
or completeness of the information provided, including information regarding a
profiled company's plans or ability to effect any planned or proposed actions.
We have no first-hand knowledge of any profiled company's operations and
therefore cannot comment on their capabilities, intent, resources, nor
experience and we make no attempt to do so. Statistical information, dollar
amounts, and market size data was provided by the subject company and related
public information sources which we believe to be reliable but we cannot
guarantee the accuracy of the information. To the fullest extent of the law, we
will not be liable to any person or entity for the quality, accuracy,
completeness, reliability, or timeliness of the information provided in the
report, or for any direct, indirect, consequential, incidental, special or
punitive damages that may arise out of the use of information we provide to any
person or entity (including, but not limited to, lost profits, loss of
opportunities, trading losses, and damages that may result from any inaccuracy or
incompleteness of this information). We encourage you to invest carefully and
read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
OTCPicks.com and affiliates have been compensated twenty thousand dollars by
the company for a four day YIPI investor awareness campaign. OTCPicks.com and
affiliates are being compensated fifty thousand dollars by a third party (New
Market Traders LTD) for a two week investor awareness campaign.